Humana jumps as Q1 results and reaffirmed 2026 outlook drive analyst re-ratings
Humana shares rose 3.74% to $249.17 as investors continued to reprice the stock after strong Q1 2026 results and reaffirmed full-year 2026 adjusted EPS guidance. The move also follows a wave of analyst price-target increases after the April 29 earnings update.
1. What’s moving the stock
Humana (HUM) traded higher Wednesday, May 6, 2026, with the stock up 3.74% to $249.17, as the market continued to digest the company’s first-quarter 2026 results and steady full-year adjusted outlook. The shares have been volatile this year as investors weigh Medicare Advantage margin pressure against membership growth and management’s longer-term profitability pathway. (humana.gcs-web.com)
2. The catalyst: Q1 results and reaffirmed adjusted guidance
Humana reported first-quarter 2026 results on April 29, 2026 and affirmed full-year 2026 adjusted financial guidance, a key support for sentiment after prior concerns tied to Medicare Advantage profitability. In the same update, Humana posted GAAP EPS of $9.83 and adjusted EPS of $10.31 for the quarter. (humana.gcs-web.com)
3. Analyst re-ratings add fuel
Following the earnings update, multiple Wall Street firms lifted price targets in early May, reflecting improved confidence that Humana can navigate 2026 headwinds while preserving its longer-term earnings framework. Recent examples include a target increase to $250 and separate target hikes to the high-$260s range after the quarter. (marketbeat.com)
4. What to watch next
Investors will focus on whether medical cost trends stabilize through the year, how Humana executes its Medicare Advantage pricing and benefit strategy, and whether incremental updates change the earnings trajectory implied by 2026 guidance. The next major scheduled catalyst is the company’s second-quarter 2026 earnings call on July 29, 2026. (humana.gcs-web.com)